glp-1/gip dual agonist mechanism of action Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Current Insights, Advantages and Challenges
Description
Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.
The preliminary data on the effect of GLP-1 RAson asthma in patients with diabetes are promising and merit further trials and research studies.
I recently received an email promoting GLP-1 support protocols
A Breakthrough Award, New Evidence in Parkinson's and Heart Disease
This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.
